Cargando…
TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
ERBB2 expression has been found in 19 to 44% of ovarian carcinomas; however, its predictive value has not been demonstrated, and trastuzumab has not found clinical application in ovarian cancer patients. We evaluated clinical significance of ERBB2 expression in relation to TP53 accumulation in ovari...
Autores principales: | Kupryjańczyk, J, Mądry, R, Plisiecka-Hałasa, J, Bar, J, Kraszewska, E, Ziółkowska, I, Timorek, A, Stelmachów, J, Emerich, J, Jędryka, M, Płużańska, A, Rzepka-Górska, I, Urbański, K, Zieliński, J, Markowska, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409772/ https://www.ncbi.nlm.nih.gov/pubmed/15545967 http://dx.doi.org/10.1038/sj.bjc.6602238 |
Ejemplares similares
-
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
por: Kupryjańczyk, J, et al.
Publicado: (2003) -
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Kupryjanczyk, Jolanta, et al.
Publicado: (2008) -
Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction
por: Kupryjánczyk, J, et al.
Publicado: (2000) -
c-erbB-2 is not a major factor in the development of colorectal cancer
por: McKay, J A, et al.
Publicado: (2002) -
TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva
por: Rolfe, K J, et al.
Publicado: (2003)